EpitoMAP Inc, Animal Allergy Clinical Laboratories Inc and Nippon Zenyaku Kogyo Co Ltd Enter into License Agreement

epitoMAP Inc. and Animal Allergy Clinical Laboratories Inc. entered into a License Agreement for an antibody pharmaceutical for veterinary use, CRE-DR-B, with Nippon Zenyaku Kogyo Co., Ltd. Under the terms of the Agreement, ZENOAQ will have the right to conduct preclinical and clinical development, manufacturing, and commercialization of CRE-DR-B for use in allergic diseases such as canine atopic dermatitis in Japan. The main therapeutic effects of existing medicines on the market are to relieve the itching caused by allergies, whereas CRE-DR-B is able to prevent the production of IgE by eliminating its producing cells.

epitoMAP and AACL will utilize the upfront payment, milestone payment and royalties (the amount and other details are undisclosed) for the continuous development of CRE-DR-B overseas, humanized CRE-DR, and a pan-coronavirus therapeutic vaccine against future emerging variants of COVID-19 as well as feline infectious peritonitis (FIP) caused by a pathogenic coronavirus in cats, FIPV, aiming at their early commercialization. "This Agreement will accelerate our collaboration with human and animal pharmaceutical companies to develop these subsequent pipelines," said Kenichi Masuda, CEO of epitoMAP.

About CRE-DR-B

CRE-DR-B is a chimeric mouse x dog IgG-B antibody originated from CRE-DR, a unique mouse monoclonal antibody that binds to both human and canine IgEs*. Since CRE-DR lacks binding to IgE on mast cells, the risk of anaphylactic shock as a major concern with anti-IgE antibody drugs can be avoided in the use of its antibody drugs. CRE-DR is able to remove the fundamental cause of allergy by eliminating and inactivating IgE-producing B cells. epitoMAP and AACL have so far succeeded in generating a caninized (CRE-DR-B) and a humanized antibody (CRE-DR-H). The commercialization of CRE-DR-B will demonstrate PoC, which can accelerate the development of CRE-DR-H.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!